pfkfb3 inhibitor

Y29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 µM, acting as a competitive inhibitor against Fru-6-P with a Ki of 0.094 µM[1].

AZ PFKFB3 26 is an effective and selective PFKFB3 inhibitor with an IC50 of 23 nM. The IC50s for PFKFB1 and PFKFB2 are 2.06 and 0.384 μM, respectively.

KAN0438757 is a selective and potent inhibitor of the metabolic kinase [PFKFB3] with an IC50 of 0.19 μM.

PFKFB4-IN-1 is a potent and selective ATP-competitive inhibitor of PFKFB4 (IC50 = 4.50 μM) that reduces intracellular PFKFB4 protein levels. It exhibits over 12-fold selectivity for PFKFB1/4 and PFKFB3/4 isoforms. PFKFB4-IN-1 inhibits cancer cell proliferation, induces apoptosis, and suppresses cell migration. It also hinders tumor growth in MDA-MB-231 xenograft mouse models. PFKFB4-IN-1 is applicable for studies related to breast cancer, lung cancer, and liver cancer.

3PO is a small-molecule inhibitor of PFKFB3 (IC50: 22.9 μM), inhibiting the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50: 1.4-24 μM). It suppresses glucose uptake, and decreases the intracellular concentration

PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).

YN1 is an inhibitor of PFKFB3 that can be used in biochemical experiments and drug synthesis research.

AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with an IC50=11nM for PFKFB3, reduces MCL-1, and inhibits angiogenesis by decreasing lactic acid production and ATP levels in endothelial cells (ECs) in tube-forming assays, and has neuroprotective effects.

PFK-158 is an effective and specific inhibitor PFKFB3.

(E)-3PO is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase) inhibitor.

AZ-PFKFB3-67 quarterhydrate is a selective and potent inhibitor of the metabolic kinase PFKFB3 kinase, acting on PFKFB3 (IC50: 11 nM), PFKFB2 (IC50: 159 nM) and PFKFB1 (IC50: 1130 nM).

PFKFB3-IN-2 is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3). Anti-sense treatment against PFKFB3 has demonstrated a reduction in tumor growth rate in vivo.